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osting by EAbstract The crude extract of the red seaweed, Asparagopsis sp. was evaluated for in vivo antibac-
terial activity against the shrimp vibrio pathogens. The algal extract was rationalized with commer-
cial shrimp feed and orally administered for different duration of time followed by the artiﬁcial
bacterial challenge experiment. In dose titration experiments, the oral administration of Asparagop-
sis sp. at a dosage of 850 mg kg–1 of biomass was highly efﬁcacious in the treatment of natural infes-
tations of Vibriosis in Penaeus monodon. The results of the conﬁrmatory dose experiment revealed
that the prophylactic treatment with moderate dose of 850 mg kg–1 of biomass day–1 for four weeks
followed by 14 days of post infection therapy was highly effective in controlling Vibrio infection in
shrimps. Moreover, results of the percent survival index and microbiological analysis clearly show
that Asparagopsis extract incorporated medicated feed had broad therapeutic potential for manag-
ing shrimp Vibriosis. In addition, in vivo trials and results obtained in this work are based on the
crude organic extract sourced from an unidentiﬁed Asparagopsis cryptic lineage, therefore further
molecular analysis to identify the species will be required.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.95722108.
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lsevier1. Introduction
Disease management in shrimp is complicated due to multifac-
eted problems such as emergence of new pathogenic strains,
resistant pathogens, misidentiﬁcation of species, short term
efﬁcacy of antibiotics, vaccines and environmental factors
(Selvin et al., 2009; Cano-Gomez et al., 2011). The balance be-
tween health and disease is a delicate one and shrimps are vul-
nerable organisms in any but ideal conditions. Sustainability of
the shrimp industry depends largely on efﬁcient disease control
and of the shrimp health (Selvin et al., 2009). Therefore, pre-
vention of the disease and the management has been consid-
ered as a priority for this industry (Roch, 1999). Globally,
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shrimps. The major species causing Vibriosis in shrimp are
Vibrio harveyi, V. ﬂuvialis, V. parahaemolyticus, V. damsela
and V. vulniﬁcus (Chythanya et al., 2002). Accurate identiﬁca-
tion of Vibrio spp. is an important factor for the effective man-
agement and control of diseases in shrimp. Recent studies
reported that multilocus sequence analysis (MLSA) is a suc-
cessful molecular tool for the identiﬁcation of Vibrio strains
(Cano-Gomez et al., 2011).
In most of the commercial shrimp farms, Vibrio prolifera-
tion has been controlled by prophylaxis and chemotherapy
(Gatesoupe et al., 1989). However the intensive and extensive
use of antibiotics and chemotherapeutics is widely criticized.
Recently, the emergence of antibiotic resistant Vibrio strains
of shrimp triggered the withdrawal of synthetic antibiotics
from aquaculture (Karunasagar et al., 1994; Hameed et al.,
2003). The lack of effective disease control has turned out to
be the cardinal limiting factor against the realization of highly
stable shrimp production. As a result to this dilemma, new
integrative disease management is therefore a critical consider-
ation in suitable shrimp production.
Among alternatives to synthetic antibiotics in shrimp aqua-
culture, use of natural products as antimicrobials has been re-
ported as a relevant strategy (Selvin et al., 2009). The use of
bioactive compounds from natural sources that enhance dis-
ease resistance in animals may be an excellent tool against
infection by pathogenic organisms. Extracts and natural prod-
ucts isolated from those plants exhibit a bewildering array of
activities in bioassays and in animal models. The application
of natural antimicrobial/immune-stimulant for disease preven-
tion in aquaculture is becoming increasingly popular due to an
increasing demand for eco-friendly aquaculture. Recently, the
therapeutic effect of botanicals has been demonstrated in
mammals (Kromna et al., 2006), birds (Mtambo et al., 1999)
and ﬁshes (Auro de Ocampo and Jimenez, 1993; Abutbul et
al., 2004; Pachanawan et al., 2008). Many marine and terres-
trial plant extracts have been investigated for antimicrobial
activity against shrimp/ﬁsh pathogens (Das et al., 1999; Bans-
emir et al., 2006; Castro et al., 2008; Tukmechil et al., 2010).
Bioactive compounds derived from algae have been used as
medicine to treat and control shrimp diseases, and successful
results have been reported from various locales globally (Chot-
igeat et al., 2004; Hou and Chen, 2005; Yeh et al., 2006, 2010;
Fu et al., 2007; Yeh and Chen, 2009). The efﬁcacy of natural
products from marine algae against various shrimp bacterial
pathogens has been demonstrated in previous studies (Jose et
al., 2008; Lipton et al., 2009; Kanjana et al., 2011). Efﬁcacy
has also been demonstrated against other shrimp pathogens
including virus such as WSSV in Penaeus monodon (Witvrouw
and De Clercq, 1997; Chotigeat et al., 2004; Manilal et al.,
2009a), Vibriosis in Fenneropenaeus chinensis (Huang et al.,
2006) and Litopenaeus vannamei (Yeh et al., 2006).
Oral administration of natural antimicrobials is the pre-
ferred route of chemotherapy in shrimp aquaculture owing
to the ease of use and lack of any additional stress to the
shrimp during treatment. Furthermore, it is impossible to iso-
late infected shrimp for the treatment purposes as done in
mammals. The application of algal-based feed may be an effec-
tive means for increasing the immune-proﬁciency and disease
resistance/control in shrimp. The disease resistance of shrimp
has been found to be induced by feeding with an algal-based
medicated feed that had been a successful strategy for diseasemanagement (Selvin et al., 2011). There has been only limited
research effort in the development of therapeutics from natural
products for shrimp disease management. Algal-based medi-
cated feed is a valuable vehicle for oral collective antibiotic
treatments in shrimps provided that an adequate amount of
the active ingredient is available for the animals. As per the
earlier in vitro studies the Asparagopsis sp. was found to be a
highly active alga from the southwest littoral of India (Manilal
et al., 2009b). Methanolic extract of Asparagopsis specimens
showed 100% inhibition against pathogenic Vibrio strains iso-
lated from moribund shrimps and MTCC culture of shrimp
Vibrio pathogens. Considering the broad anti-Vibrio potency,
less in vitro shrimp toxicity (Manilal et al., 2010a) and huge
biomass availability, Asparagopsis sp. is well suited for the
development of potential therapeutic agent. In this back-
ground, the aims of the present study are: to determine the
in vivo efﬁcacy of Asparagopsis extract incorporated feed for
the treatment of disease due to experimental infection with
respective pathogenic Vibrio spp. and to establish the effective
dose level in the treatment of Vibriosis.
2. Materials and methods
2.1. Collection and extraction
Specimens of Asparagopsis sp. were sourced from the intertidal
biotope of Kollam littoral (08540N and 76380E), India. It is
one of the more common red algae in the Southwest littoral
of Kollam prefecture. The extract of Asparagopsis sp. was pre-
pared by standardized procedure as described by Manilal et al.
(2009b).
2.2. Preparation of medicated feed and formulation
The doses of Asparagopsis extract for shrimp disease treatment
was selected according to minimum inhibitory concentration
values against pathogenic Vibrio and toxicological data (Man-
ilal et al., 2009b, 2010a). Considering the facts that parenteral
(intra-muscular injection) median lethal dose (480 mg kg–1
shrimp; Manilal, 2011) may not be lethal in oral intubation
(Loomis, 1978) the following dosing regimens were preferred
to attain effective therapeutic values. To prepare the medicated
feed 250, 500, 750, 1000, 1250 and 1500 mg of ethyl acetate
partitioned fraction of Asparagopsis sp. suspended in 100 mL
of 6% gelatin water. The mixture was thoroughly sprayed on
1000 g of commercial pellet feed (Charoen Pokphand India
Pvt. Ltd.) using a TLC sprayer (Xu and Rogers, 1994). Finally,
the wet pellets were dried in an oven at 40 C for about 12 h to
achieve the ﬁnal moisture content (about 8%). The control
feed was prepared by coating feed pellets with gelatin in the
same proportion as used for the medicated feed.
2.3. Determination of effective dose of medicated feed (in vivo
dose titration study)
Test doses were calculated as intake of the active substance per
kilogram biomass per time. Therefore, data on lower, moderate
and higher regimen are necessary. In order to determine an
appropriate dosage regimen, two dose titration trials were per-
formed. In the ﬁrst set of preliminary experiments, four dose reg-
imens (285, 575, 850 and 1150 mg kg1) of medicated feed were
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algae extract was incorporated as extra (Manilal, 2011). Based
on the results from previous dose titration study, a second set
of dose titration experiments was performedwith three dose reg-
imen (575, 850 and 1150 mg kg1) of medicated feed. Two trials
were identical except for a very slight difference in shrimp size
and number of dose levels of medicated feed.
2.4. Shrimp experimental system and maintenance
P. monodon juveniles (PL-20; 500 Nos.) were obtained from
the large-scale hatchery of Matsyafed, Kollam, Kerala, and
acclimatized to standard conditions: 25 ± 2 C, 15&, and con-
stant aeration. After three weeks of nursing phase, shrimps
that had no signs of disease were selected for experiment. After
the initially biometric analysis (3.1 ± 1.2 cm), shrimps were di-
vided into ﬁve groups and randomly stocked at a density of
100 shrimps in each rectangular 2000 L capacity Fiber Rein-
forced Plastic (FRP) tanks. The results of preliminary animal
feeding behavior to various dose levels indicated that shrimps
exhibited a 60–70% of deterrent behavior in higher doses (1450
and 1725 mg kg1) of medicated feed. Therefore, these dose
levels were excluded for further titration trials. For the ﬁrst
dose titration studies, the experimental design consists of four
nominal doses (285, 575, 850 and 1150 mg kg1 biomass) of
medicated feed. Shrimps in the control group were kept un-
treated and fed with normal commercial feed. The shrimps
were fed with their allocated medicated feed of 3.5% of the
body weight three times a day regularly until the end of exper-
iment. Approximately 25% of the total water volume was re-
placed daily to maintain water quality. During the course of
experiment, temperature (25 ± 2 C), dissolved oxygen of
water (6 mg L1) and the salinity (15 ± 1.5&) were measured
daily using the Hach kit model (Hach Company, Loveland,
CO). However, in the ﬁrst dose titration study, higher percent-
age of mortalities (disease sensitive) occurred in the lower dose
(285 mg kg1) of medicated feed. For this reason, lower dose
was occluded and a second dose titration study was performed.
The treatments which achieved highest (disease resistant) sur-
vival rate were selected to be used for further dose titration
study. The same experiment was repeated with three dose lev-
els (575, 850 and 1150 mg kg1 biomass) of medicated feed in
the second dose titration.
2.5. Challenge experiments using Vibrio spp.
After three weeks of feeding trial, ten shrimps from each group
(medicated and control groups) were individually challenged
with four species of live Vibrio: V. harveyi, V. alginolyticus,
V. parahaemolyticus and Photobacterium damsela (Manilal
et al., 2010b). The in vivo challenge experiment was performed
as per Manilal et al. (2012). The challenged animals were mon-
itored for a period of two weeks for mortality and infections.
During the challenge period, the shrimps were fed continu-
ously with their respective feeds. The cause of death/infection
was ascertained by re-isolating the respective organism from
the shrimp body and subjecting the isolates to standard bio-
chemical tests. The morbidity and mortality were recorded dai-
ly and ﬁnal mortality was evaluated after two weeks of post
challenge, percentage of mortality was calculated as per Man-
ilal et al. (2012):Mortalityð%Þ ¼ No: of dead shrimps A
Total No: of shrimps A 100
where ‘‘A’’ represents the number of dead shrimps on the ﬁrst
day after challenge. This mortality rate could be considered as
a result of handling stress.The percent of survival index (ther-
apeutic efﬁcacy) was calculated as
Percent Survival IndexðPSIÞ
¼ 1 % of specific moralities in treated group
% of specific moralities in control group
 
 1002.6. Determination of optimum time of dosing (time titration
study)
This study was conducted to ascertain whether the duration of
pre-feeding (prophylactic) and post-feeding (therapeutic) of
effective dosage had inﬂuence on the survival and infection
of the shrimps. At the same time, in another experimental set
up, time titration studies were also carried out to determine
the efﬁcacy of best formulation (850 mg kg1) prophylactically
and therapeutically in different dosing intervals (21 and
28 days). Medication was given for the recommended dura-
tion, with replicates, as follows: Group I: shrimps fed with
medicated feed 21 days prior to challenge and subsequent
14 days feeding with normal feed. Group II: shrimps fed with
medicated feed 21 days prior to challenge and subsequent
14 days feeding with medicated feed. Group III: shrimps fed
with medicated feed 28 days prior to challenge and subsequent
two weeks feeding with normal feed. Group IV: shrimps fed
with medicated feed 28 days prior to challenge and subsequent
two weeks feeding with medicated feed. The experimental facil-
ities, source of the post-larvae, maintenance and challenge
experiments were identical to those in the dose titration trials.
2.7. In vivo conﬁrmatory experiments on shrimp disease control
using effective dose of algal extracts
Conﬁrmatory titration trial was designed to determine whether
the proposed dose level is effective against single and mixed
challenge experiment. A batch of healthy P. monodon was di-
vided into two subgroups were fed with 850 mg kg1 medi-
cated feed while the control group was fed on the normal
feed (feed free from Asparagopsis extract). The experimental
design, feeding pattern, water management system, facilities
and the size of shrimp used in conﬁrmatory experiment were
analogous those used in the dose titration studies. At the con-
clusion of fourth week of the feeding period, 10 shrimps from
each group were challenged with appropriate single and mixed
culture of bacterial suspension (Manilal et al., 2012). The
inoculums were prepared by deliberate mixing of different spe-
cies (V. harveyi+ V. alginolyticus; V. harveyi+ V. parahae-
molyticus; V. harveyi+ Ph. damsela) of bacteria of known
doses (ca. 5 · 102 + 5 · 102). Each challenge experiment was
carried out in triplicate. For microbiological analysis, 20%
of the animals from each group were analyzed.
2.8. Data analysis
All the data are presented as mean ± standard deviation
(S.D.). Mean values were compared among treatments and
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SPSS for Windows version 11.2 (SPSS, Chigago, IL, USA).
3. Results
3.1. In vivo dose titration trials
The overall objective of the dose titration trial is to evaluate
the ability of shrimp fed with medicated feed of different dose
levels to overcome the challenge experiment. In the initial dose
titration trial, shrimps were orally administered at the rate of
285, 575, 850 and 1150 mg kg1 biomass for three weeks and
subsequently challenged with respective Vibrio spp. The results
of the dose titration proﬁles were summarized in the Table 1.
After infection with challenge inocula of respective Vibrio
spp. (ca. 105 CFU animal1), medicated feed treated groups
proved to be effective in increasing the survival rate of shrimp.
The efﬁciency of the medicated feed varied with different dos-
age rates, type of Vibrio spp. challenged and treatment sche-
dule. There was an apparent correlation between percent
survival index of the shrimp and dose levels of medicated feed.
At the end of the post challenge treatment period, cumulative
mortalities and morbidities of the shrimp treated with moder-
ate and higher dose of medicated feed was signiﬁcantly lower
than that of non-medicated group (control group). Non-med-
icated shrimps had severe infection and mortality. In contrast,
all of the unchallenged control shrimps survived throughout
the experimental period and was microbiologically negative
for Vibriosis. This observation clearly conﬁrmed that shrimps
were not carrying the bacteria prior the start of the experimen-
tation. The percent survival index of shrimp fed with 850 and
1150 mg kg1 was signiﬁcantly superior to any of the medi-
cated group of shrimp and ranged between 53 and 67 afterTable 1 First dose titration trial of control and medicated shrimp
respective Vibrio spp.
Treatment regimens (mg kg1) Mean % infection and mortality
VH VA
%I %M %I
285 85 ± 5.2 82 ± 1.6 83 ± 5.5
575 74 ± 4.2 57 ± 1.8 63 ± 4.3
850 37 ± 3.5 35 ± 2.5 21 ± 4.7
1150 55 ± 4.7 35 ± 2.2 46 ± 5.2
+Control 100 100 100
–Control 0 5 0
Mean ± SD; VH – V. harveyi; VA – V. alginolyticus; VP – V. parahaem









VH – V. harveyi; VA – V. alginolyticus; VP – V. parahaemolyticus; PD –the challenge experiment (Table 2). Only two dose levels of
medicated feed (850 and 1150 mg kg1) signiﬁcantly inhibited
the Vibrio infection. The degree of morbidity in the challenged
shrimps was signiﬁcantly lower in these dose levels. However,
the lower doses (575 mg kg–1) of medicated feed were also
found to increase the percent survival index of shrimp but
the percentage of infection was higher. At the end of the exper-
iment, the percent survival index of 575 mg kg–1 treated shrimp
ranged between 29 and 43 (Table 2). At this dose, the shrimp
challenged with lethal dose of V. harveyi, caused morbidity
to the extent of 74% while shrimps that injected with V. algi-
nolyticus, V. parahaemolyticus and Ph. damsela caused 63%,
65% and 60%, respectively. The reason may be due to the
insufﬁcient administration and bioavailability of the medica-
tion in this treatment. The rate of mortality and morbidity in
285 mg kg1 treated group was higher than in other treat-
ments. The shrimps treated with 285 mg kg1 resulted in aver-
age 61% mortality. The severity of infection was higher in this
group and majority of the treated shrimps at this dose levels
exhibited pathological signs such as feeble movement, dark
body coloration, necrosis of legs, antenna and tail. By con-
trast, challenged control specimens fed with normal feed expe-
rienced 100% of infection and mortality was ranging between
60% and 100%. The lower doses of medicated feed were found
to be unpromising candidates and therefore eliminated in the
further experiment.
In the second dose titration study, the preferred dose levels
of medicated feed were administered at 850 and 1150 mg kg1
biomass for three weeks. The results indicate that treatment
with both dose levels of medicated feed was an effective means
of reducing the prevalence of infection due to Vibriosis. The
oral administration of Asparagopsis extract incorporated med-
icated feed at 850 and 1150 mg kg1 dose levels evidently in-s received different dose levels for 21 days and challenged with
VP PD
%M %I %M %I %M
53 ± 2.5 81 ± 6.2 55 ± 1.3 82 ± 3.2 54 ± 1.5
41 ± 2.3 65 ± 2.8 44 ± 2.7 60 ± 2.5 43 ± 1.9
24 ± 1.1 18 ± 5.4 22 ± 1.1 20 ± 2.8 24 ± 2.0
30 ± 2.1 41 ± 5.2 29 ± 2.3 43 ± 3.2 25 ± 2.3
64 ± 2.4 100 67 ± 2.1 100 61 ± 1.5
5 0 5 0 5








Table 3 Second dose titration trial of control and medicated shrimps received 850 and 1150 mg kg1 of dose levels for 21 days and
subsequently challenged (ca.105 CFU shrimp1) with respective Vibrio spp.
Treatment regimens (mg kg1) Mean % infection (I) and mortality (M)
VH VA VP PD
%I %M %I %M %I %M %I %M
850 31 ± 2.3 32 ± 2.5 18 ± 2.6 21 ± 2.5 16 ± 3.9 20 ± 2.8 19 ± 3.5 21 ± 2.2
1150 51 ± 3.5 36 ± 2.2 40 ± 2.9 27 ± 2.8 45 ± 4.2 23 ± 3.5 39 ± 3.4 26 ± 3.1
+Control 100 100 100 61 ± 1.5 100 64 ± 1.8 100 68 ± 2.2
– Control 0 5 0 5 0 5 0 5
Mean ± SD; VH – V. harveyi; VA – V. alginolyticus; VP – V. parahaemolyticus; PD – Ph. damsela.




VH VA VP PD
850 68 65 68 69
1150 64 55 64 61
VH – V. harveyi; VA – V. alginolyticus; VP – V. parahaemolyticus; PD – Ph. damsela.
Table 5 Efﬁcacy of medicated feed on protection and survival of experimentally infected P. monodon.
Treatment regimens Mean % infection (I) and mortality (M)
VH VA VP PD
I% M% I% M% I% M% I% M%
Group I 36 ± 2.5 38 ± 2.1 27 ± 5.3 31 ± 1.2 29 ± 5.7 26 ± 2.2 34 ± 1.8 28 ± 1.9
Group II 35 ± 3.4 34 ± 1.7 28 ± 2.7 25 ± 1.6 20 ± 3.1 18 ± 2.1 25 ± 1.5 22 ± 3.1
Group III 31 ± 4.7 25 ± 1.4 25 ± 4.2 22 ± 2.5 22 ± 4.3 21 ± 3.5 21 ± 3.5 19 ± 1.5
Group IV 26 ± 3.1 17 ± 2.2 23 ± 5.5 14 ± 1.9 22 ± 2.8 10 ± 1.5 20 ± 2.3 12 ± 4.2
+Control 100 100 100 64 ± 1.5 100 61 ± 1.5 100 62 ± 3.1
–Control 0 0 0 0 0 0 0 0
VH – V. harveyi; VA – V. alginolyticus; VP – V. parahaemolyticus; PD – Ph. damesla.
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infection suggesting that medicated feed had efﬁcient and
desirable inﬂuence on resistance of P. monodon to Vibriosis.
Both dosage regimens are slightly different in terms of percent
survival index pattern (Table 4). Regarding the percentage of
infection, the moderate dose level of 850 mg kg1 day1 was
signiﬁcantly more efﬁcacious than 1150 mg kg1 day1 treated
group (Table 3). The shrimps treated with 850 mg kg1 of
Asparagopsis extract and following challenge with V. alginolyt-
icus, V. parahaemolyticus and Ph. damsela displayed less than
20% of mild infection, whereas V. harveyi caused 31% infec-
tion. The severity of infection in the 850 mg kg1 treated group
was mild. The infected shrimp exhibited feeble movement and
anorexia during the ﬁrst three to four days of infection and
recovered after ecdysis. It was notable that the proliferation
of shrimp Vibrios to cause mass mortality in the host was con-
siderably prevented in the shrimp treated with 850 mg kg1
Asparagopsis extract. However, the degree of morbidity in
1150 mg kg1 treated groups was in the range of 39–45%
against V. alginolyticus, V. parahaemolyticus and Ph. damsela
and 51% against V. harveyi. The infected shrimps were lethar-
gic and anorectic during the post challenge period. In infectedshrimps under medication, the molting process was regained
within 15 days of treatment.
3.2. Effect of treatment duration on the survival and infection
In time titration study, group IV type of treatment regimen sig-
niﬁcantly reduces pathological signs and mortality (Table 5).
Indeed, there was a trend for lower mortality and lesser path-
ological signs. Although spontaneous recoveries do not occur,
infection may continue for four to ﬁve days and lessened com-
pletely after the 14th day of treatment. The rate of mortality
was also diminished dramatically to 13.25% (10–17%). The
degree of infection signiﬁcantly increased in groups (I and
III) fed with normal feed after challenge experiment. This
may be attributed to the colonization of Vibrios due to the dis-
continuation of medicated feed. It is assumed that, cessation of
medicated feed after challenge experiment provided ample
opportunity for surviving Vibrios to multiply. The study re-
vealed that the treatment for shrimps should always be at an
optimum protective dose of 850 mg kg1 biomass day1 for
four weeks and has to be fed for a minimum of two weeks even
if it appears to have recovered from the infection. Therefore,
Table 6 Efﬁcacy of Asparagopsis extract incorporated feed (850 mg kg–1) and PSI of P. monodon towards shrimp pathogens.










V. harveyi 105 97.3 ± 2.2 19.8 ± 1.5 79.6 25 ± 4.5
V. alginolyticus 105 62.3 ± 1.8 15.7 ± 1.3 74.7 18 ± 3.2
V. parahaemolyticus 105 64.6 ± 1.4 10.6 ± 2.5 83.5 15 ± 2.8
Ph. damsela 105 58.7 ± 2.5 11.2 ± 2.2 80.9 17 ± 3.1
V. harveyi+ V. alginolyticus 5 · 102 + 5 · 102 98.5 ± 1.4 35.8 ± 1.4 63.6 45 ± 4.8
V. harveyi+ V. parahaemolyticus 5 · 102 + 5 · 102 95.6 ± 2.3 31.3 ± 2.5 67.2 38 ± 5.2
V. harveyi+ Ph. damsela 5 · 102 + 5 · 102 94.2 ± 1.8 32.1 ± 1.7 65.9 41 ± 3.5
* Mean ± SD; n= No of shrimps used for the experiment.
170 A. Manilal et al.feeding lower dose of medicated feed or decreasing the number
of days (28 days of prophylatic and 14 days of therapeutic
intervals) can permit the bacterial pathogens to resurface.
3.3. In vivo conﬁrmatory experiments on shrimp disease control
using effective dose of algal extract
The results of efﬁcacy validation envisaged that, shrimp fed
with 850 mg kg1 medicated feed experienced a signiﬁcant in-
crease in the percent survival index relative to control groups
(Table 6). The survival rate of treated and control shrimps
against various Vibrio pathogens is depicted in Figs. 1–4.
The mortality rate of medicated shrimp challenged with single
culture of pathogens viz., V. harveyi, V. alginolyticus, V. para-
haemolyticus and Ph. damsela were 19.8 ± 1.5%, 15.7 ±
1.3%, 10.6 ± 2.5% and 11.2 ± 2.2%, resulting in percent sur-
vival index of 79.6 ± 1.5, 74.6 ± 1.3, 83.5 ± 2.5 and 80.9 ±
2.2, respectively, whereas in the control group, the mortality
rate was 97.3 ± 2.2, 62.3 ± 1.8% 64.6 ± 1.4% and
58.7 ± 2.5%. The clinical signs and mortalities of control
group are consistent with the earlier pathogenicity studies. In
treated shrimps, mortality began on the 48th hour after expo-
sure to V. harveyi and continued for approximately 24 h. The
onset of mortality was after 72 h in V. alginolyticus, V. para-
haemolyticus and Ph. damsela injected groups. Half of the con-
trol shrimps died 48 h after inoculation with V. harveyi and
mortality raised above 80% in 24 h and after that.
Challenged animals began to exhibit pathological signs 24 h
after injection. The degree of infection was below 25% in V.
harveyi inoculated groups whereas, V. alginolyticus, V. para-
haemolyticus and Ph. damsela caused less than 18% of infec-
tion. Duration of infection ranged from three to six days or
more. Following ten days of medicated feed treatment, the
pathological signs were averaged for each animal for everyday.
The higher degree of percent survival index and lower degree
of morbidities could be an indication of improved health status
of shrimp fed with this medicated feed.
The shrimps challenged with mixed culture of pathogen
produced more infection or mortality in the treated group than
those caused by the single culture of pathogen (Figs. 5–7). The
percent survival indices of shrimps challenged with mixed cul-
ture of pathogens (V. harveyi+ V. alginolyticus; V. har-
veyi+ V. parahaemolyticus; V. harveyi+ Ph. damsela) were
63.6 ± 1.4, 67.2 ± 2.5, 65.9 ± 1.7, respectively. The onset of
the mortality was after 24 h in treated groups and reachedca. 35% in 48 h. While in control groups the mortality began
after 24 h and scaled up to 90% on 72 h of post challenge.
The shrimps injected with the mixture of Vibrio culture exhib-
ited an average 41.3% of infection. The severity of infection
was higher during the 72 h of post challenge in survivor
shrimp. The closed observation of infected shrimps revealed
several clinical symptoms of Vibriosis such as discoloration
(dark spot), atypical swimming, empty digestive tract and
aversion to feed. These symptoms were completely recovered
after twelve to fourteen days of medicated treatment. At the
end of the experiment, majority of the shrimps exhibited the
same external signs of health like quick movements, bright col-
or and lack of disease as it was in the beginning. The shrimps
that survived the Vibrio challenge or that recovered after med-
ication molted at a rate analogous to that of the unchallenged
shrimps. Accordingly, the same dosage regimen is often prag-
matically recommended for the management of single and
mixed culture of Vibrio challenge.
3.4. Bacteriological enumeration
Bacterial vegetation densities were determined in medicated
and untreated controls at the beginning and the end of the
experiment. Regarding the Vibrio count in shrimps challenged
with single species of Vibrio culture, the rapid proliferation of
Vibrio was successfully arrested in the treated group relative
to the control. The Vibrio count was initially high in treated
groups and further decreased as the experiment progressed.
Mean bacterial densities for medicated shrimp at initiation
of post challenge treatment was 8.2 · 104. Following 14 days
of treatment with medicated feed, proliferation of Vibrio spp.
was suppressed in treated shrimps. The density of Vibrios de-
clined steadily from 105 to 101 CFU mL1 in the majority of
medicated shrimps that underwent ecdysis. In contrast, the
Vibrio count in control groups remained steady toward the
end of the experiment. On the other hand, shrimps injected
with NS (negative control) showed few numbers of Vibrio
spp. in hepatopancreas. The presence of bacteria in the neg-
ative control group may be explained by the entrance of
microorganisms from the water through the wound caused
by the injection. There was no signiﬁcant difference in Vibrio
count among the four different challenged control groups.
The mean bacterial density for survivor shrimp ranged from
1.38 · 101 to 4.23 · 101 CFU mL–1 on the 16th day of post
challenge period.
Figure 1 Survival rate of medicated and non-medicated P. monodon challenged with single culture of V. harveyi.
Figure 2 Survival rate of medicated and non-medicated P. monodon challenged with single culture of V. alginolyticus.
Figure 3 Survival rate of medicated and non-medicated P. monodon challenged with single culture of V. parahaemolyticus.
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lenged with mixed culture of Vibrio revealed that there was a
gradual reduction in the Vibrio count of treated groups relative
to the control group. The mean bacterial density in treated
group was ca. 101 and 105 CFU mL1 in the untreated control
group on the 16th day of microbiological examination. In the
medicated shrimp challenged with V. harveyi+ V. alginolyti-
cus, the bacterial density was 8.3 ± 0.5 · 104 in the 1st dayof the experiment, which reduced to 4.2 ± 0.2 ·
101 CFU mL–1 on the 16th day of experiment, whereas in the
control this value remained steady during the post challenge
days. The Vibrio count was signiﬁcantly reduced in the speci-
mens that underwent ecdysis. The medicated groups chal-
lenged with V. harveyi+ V. parahaemolyticus and V.
harveyi+ Ph. damsela also exhibited similar pattern of reduc-
tion in Vibrio count during the end of the experiment.
Figure 4 Survival rate of medicated and non-medicated P. monodon challenged with single culture of Ph. damsela.
Figure 5 Survival rate of medicated and non-medicated P. monodon challenged with mixed culture of V. harveyi+ V. alginolyticus.
Figure 6 Survival rate of medicated and non-medicated P. monodon challenged with mixed culture of V. harveyi+ V. parahaemolyticus.
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4.1. In vivo dose titration trials
The results of this preliminary dose titration trial suggest that
the treatment with moderate dose level of medicated feed in-
creases or confers considerable disease resistance in P. mon-
odon. This study also revealed that the higher doses of algal
extract may not be beneﬁcial to animal performance and the
lower doses did not inﬂuence the Vibrio count after infection.Based on these results, moderate dose levels (850 and
1150 mg kg1) exhibiting highest efﬁcacy was preferred for
subsequent experiments.
The efﬁcacy of algalmetabolites on the survival of shrimp de-
pends on the source of algae, concentration of algal metabolites,
administration route and exposure time. In the second dose
titration study, 850 mg kg1 treatment was shown to be more
potent than the 1150 mg kg1. This may be due to the difference
in the content of extract in two preparations which in turn inﬂu-
ence the feed intake and efﬁcacy. It probably concluded that the
Figure 7 Survival rate of medicated and non-medicated P. monodon challenged with mixed culture of V. harveyi+ Ph. damsela.
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disease resistance of P. monodon is dose-dependent and
850 mg kg1 is an optimal dose after three weeks of feeding
against Vibrio infection. The optimal dosage rate and adminis-
tration schedule are integral agents governing the effectiveness
of a drug, therefore further experiments are obviously war-
ranted to determine the duration of feeding regime.
Vibrios are continued to be a signiﬁcant cause of morbidity
and mortality in shrimp aquaculture, and they are frequent iso-
lates causing Vibriosis. The multi-resistance of these isolates
plays an important role in the colonization or infection of P.
monodon. The application of algal metabolites for the manage-
ment of infectious pathogens of P. monodon was reported to
be most effective by different workers (Selvin et al., 2009; Jose
et al., 2008). The results obtained in the present study conﬁrm
preliminary evaluation by Selvin et al. (2011) that Ulva diet is
effective against Vibrio infestation in P. monodon. The results
of the present study extend previous observations on the
in vivo efﬁcacy of microalgae Tetraselmis suecica for the control
of Vibrio spp. in a commercial shrimp hatchery of the white
prawn F. indicus (Regunathan and Wesley, 2004). Immanuel
et al. (2004) demonstrated that herbal and algal extracts may
be effectively used as a dietary source to enhance the disease
resistance as well as to have better survival and production of
P. indicus in aquaculture systems. Banana shrimp F. merguiensis
fed with S. platensis showed resistance against V. harveyi infec-
tion (Lee et al., 2003).L. vannamei treatedwith hot-water extract
of Gracilaria tenuistipitata via injection displayed resistance
against V. alginolyticus (Hou and Chen, 2005). Leano et al.
(2007) reported the efﬁcacy of stevia extract in enhancing disease
resistance of juvenile P. monodon against V. harveyi. According
to Yeh et al. (2009) treatment with twig hot-water extract from
Cinnamomum kanehirae can enhance disease resistance of white
shrimp to V. alginolyticus. Tayag et al. (2010) reported that L.
vannamei that received extract of Spirulina platensis showed in-
creased resistance against V. alginolyticus. Recently, Manilal
et al. (2012) envisaged the effect ofAcrosiphonia orientalis incor-
porated medicated feed on the survival rate of P. monodon
against V. harveyi and V. alginolyticus infection.
4.2. Effect of treatment duration on the survival and infection
One of the important parameters to be determined for the
development of rational dose regimen is the optimal durationof administration. A period of 28 days of prophylactic medica-
tion followed by 14 days of post challenge therapy was sufﬁ-
cient to manage the severity and resurgence of infection to a
great extent. This treatment regimen was signiﬁcantly superior
to other treatment in reducing the degree of morbidity. The
reason for this efﬁcacy may be related to prompt treatment
with effective dosage of medicated feed which prevents bacte-
rial re-growth even after the challenge experiment. Manilal
et al. (2012) reported that prophylactic treatment with
1200 mg kg–1 of A. orientalis extract for a period of 28 days
and subsequent two weeks of post challenge therapy was an
effective means of controlling vibriosis in P. monodon. Simi-
larly, P. monodon following 15 days feeding on Ulva diet at a
dose level of 1000 mg kg1 enhanced its survival rate against
vibrio infection (Selvin et al., 2011). Pholdaeng and Pongsam-
art (2010) reported that P. monodon pre-fed with Durio zibethi-
nus supplemented diet showed higher disease resistance with
both viral and bacterial pathogens than in the control group.
4.3. In vivo conﬁrmatory experiments on shrimp disease control
using effective dose of algal extract
The conﬁrmatory experiment was aimed to optimize the dose
level of Asparagopsis extract required by experimentally in-
fected P. monodon for survival. Therefore, 850 mg of Asparag-
opsis extract incorporated feed with optimal feeding schedule
which exhibited higher efﬁcacy in dose/time titration experi-
ment was preferred. In general, the percent survival index of
shrimps challenged with single and mixed culture of pathogens
was signiﬁcantly higher than that of control groups. It has
been reported that hot-water extract of red alga Gelidium
amansii increased the resistance of L. vannamei against V. alg-
inolyticus (Fu et al., 2007). Similarly, Yeh and Chen (2009)
showed that survival rates of shrimp immersed in hot-water ex-
tract of Gracilaria tenuistipitata were signiﬁcantly higher than
those of control shrimp. In addition, G. tenuistipitata also
had a beneﬁcial effect on the prevention and treatment for Vib-
rio disease in L. vannamei (Hou and Chen, 2005).
The conﬁrmatory study revealed that prompt and effective
administration of effective dose level of medicated feed eradi-
cated the Vibrios from experimentally challenged animals. In
the present study, survival rate and degree of infection in effec-
tive dose treated shrimp varied in the single and mixed patho-
genic exposure. The reason for the difference in the efﬁcacy of
174 A. Manilal et al.the effective dose related to different factors such as the route of
pathogenic challenge, virulence of the pathogen, environmental
and physiological factors affecting both pathogens and hosts.
Themedicated feed rationalized with 850 mg kg–1ofAsparagop-
sis extract was manifold. This effective dose level was found to
be optimal for the control of four pathogenic Vibrio species.
In addition, the experiment proves that the same feeding regi-
men is enough for the management of single and mixed culture
ofVibrio infection inP. monodon. In the present study, bacterial
concentration in the experimentally infected medicated shrimp
subsequently reduced upon treatment.
The oral administration with medicated feed provided com-
plete recovery of clinical signs in the experimentally infected
shrimp in treatment. The ability of medicated feed to reduce
the Vibrio load in the treated shrimp could be due to the anti-
bacterial effect of Asparagopsis sp. (Manilal et al., 2009a). The
increased disease resistance in P. monodon fed algal-based
medicated feed after pathogen challenge is in line with other
studies (Selvin et al., 2009, 2011; Manilal et al., 2012). The pro-
tective and therapeutic effect of Asparagopsis extract in
defending shrimps from infections could be attributed due to
the presence of halogenated compounds (Paul et al., 2006). It
has been claimed that the antibacterial effect of Asparagopsis
sp. has a broad spectrum (Manilal et al., 2009a).
5. Conclusion
The crude extract of themarine red algae species ofAsparagopsis
was rationalizedwith commercial shrimp feed and orally admin-
istered for different duration of time followed by the artiﬁcial
bacterial challenge experiment. In dose titration experiments,
the oral administration of Asparagopsis sp. at a dosage of
850 mg kg–1 of biomass was highly efﬁcacious in the treatment
of natural infestations of Vibriosis in P. monodon. The results
of the conﬁrmatory dose experiment revealed that the prophy-
lactic treatment with moderate dose of 850 mg kg–1 of biomass
day–1 for four weeks followed by fourteen days of post infection
therapy was highly effective in controlling Vibrio infection in
shrimps. Based on the present ﬁndings, it could be inferred that
the secondary metabolites of Asparagopsis sp. may be an excel-
lent source for developing potent and cost effective formulations
for sustainable shrimp farming. In addition to this, it is neces-
sary to identify the exact lineage ofAsparagopsis sp. from Indian
littoral by molecular characterization. Therefore, further inves-
tigations both with the aim of identifying the taxonomic lineage
and to evaluate the mechanism of action of algal extract on
shrimp immunity are warranted.Acknowledgment
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